Hologic, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US4364401012
USD
74.86
0.04 (0.05%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Hologic, Inc. stock-summary
stock-summary
Hologic, Inc.
Pharmaceuticals & Biotechnology
Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.
Company Coordinates stock-summary
Company Details
250 Campus Dr , MARLBOROUGH MA : 01752-3020
stock-summary
Tel: 1 508 26329001 858 4108588
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 143 Schemes (45.93%)

Foreign Institutions

Held by 379 Foreign Institutions (33.61%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Stephen MacMillan
Chairman of the Board, President, Chief Executive Officer
Ms. Sally Crawford
Lead Independent Director
Mr. Charles Dockendorff
Independent Director
Mr. Scott Garrett
Independent Director
Dr. Ludwig Hantson
Independent Director
Mr. Namal Nawana
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
1,024 Million
(Quarterly Results - Jun 2025)
Net Profit:
195 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 17,704 Million (Small Cap)

stock-summary
P/E

21.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.13

stock-summary
Return on Equity

16.75%

stock-summary
Price to Book

3.66